CoChat

A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents

Open access
Mietlicki‐Baase, Elizabeth G., Liberini, Claudia G., Workinger, Jayme L., Bonaccorso, Ron L., Borner, Tito, Reiner, David J., Koch‐Laskowski, Kieran, McGrath, Lauren E., Lhamo, Rinzin, Stein, Lauren M., De Jonghe, Bart C., Holz, George G., Roth, Christian L., Doyle, Robert P., Hayes, Matthew R. · 2018 · Diabetes, Obesity and Metabolism
Cited by 36

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Aims: While pharmacological glucagon‐like peptide‐1 receptor (GLP‐1R) agonists are FDA‐approved for treating type 2 diabetes mellitus (T2DM) and obesity, a major side effect is nausea/malaise. We recently developed a conjugate of vitamin B12 (B12) bound to the GLP‐1R agonist exendin‐4 (Ex4), which displays enhanced proteolytic stability and retention of GLP‐1R agonism. Here, we evaluate whether the conjugate (B12‐Ex4) can improve glucose tolerance without producing anorexia and malaise. Materials and methods: We evaluated the effects of systemic B12‐Ex4 and unconjugated Ex4 on food intake and body weight change, oral glucose tolerance and nausea/malaise in male rats, and on intraperitoneal glucose tolerance in mice. To evaluate whether differences in the profile of effects of B12‐Ex4 vs unconjugated Ex4 are the result of altered CNS penetrance, rats received systemic injections of fluorescein‐Ex4 (Flex), Cy5‐B12 or Cy5‐B12‐Ex4 and brain penetrance was evaluated using confocal microscopy. Uptake of systemically administered Cy5‐B12‐Ex4 in insulin‐containing pancreatic beta cells was also examined. Results: B12‐Ex4 conjugate improves glucose tolerance, but does not elicit the malaise and anorexia produced by unconjugated Ex4. While Flex robustly penetrates into the brain (dorsal vagal complex, paraventricular hypothalamus), Cy5‐B12 and Cy5‐B12‐Ex4 fluorescence were not observed centrally, supporting an absence of CNS penetrance, in line with observed reduction in CNS‐associated Ex4 side effects. Cy5‐B12‐Ex4 colocalizes with insulin in the pancreas, suggesting direct pancreatic action as a potential mechanism underlying the hypoglycaemic effects of B12‐Ex4. Conclusion: These novel findings highlight the potential clinical utility of B12‐Ex4 conjugates as possible future T2DM therapeutics with reduced incidence of adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13222

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 36

Metadata

Authors
Mietlicki‐Baase, E. G., Liberini, C. G., Workinger, J. L., Bonaccorso, R. L., Borner, T., Reiner, D. J., Koch‐Laskowski, K., McGrath, L. E., Lhamo, R., Stein, L. M., De Jonghe, B. C., Holz, G. G., Roth, C. L., Doyle, R. P., & Hayes, M. R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2018-02-20
Volume
20
Issue
5
Pages
1223-1234
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2782759123
Cited by
36
References
21
FWCI
3.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents. https://app.cochat.ai/papers/10.1111/dom.13222
The paper
Mietlicki‐Baase, E. G., Liberini, C. G., Workinger, J. L., Bonaccorso, R. L., Borner, T., Reiner, D. J., Koch‐Laskowski, K., McGrath, L. E., Lhamo, R., Stein, L. M., De Jonghe, B. C., Holz, G. G., Roth, C. L., Doyle, R. P., & Hayes, M. R. (2018). A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13222

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.